Gomez Lilian Sales, Jurk Diana
Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Subcell Biochem. 2024;107:91-116. doi: 10.1007/978-3-031-66768-8_5.
Cellular senescence is recognised as a contributor to the ageing process and the development of multiple age-related conditions. Researchers have launched efforts to identify compounds capable to selectively kill senescent cells, known as senolytics, without affecting non senescent cells. As of now, over 40 compounds have demonstrated senolytic properties, offering promising prospects for reversing or ameliorating age-related conditions in preclinical studies.This chapter presents the most recent developments in senolytic drug research, encompassing investigations spanning basic science, preclinical trials, and clinical studies. While many of these investigations have generated encouraging results in the realm of age-related interventions, this chapter also addresses potential challenges and pitfalls.
细胞衰老被认为是衰老过程和多种与年龄相关疾病发展的一个促成因素。研究人员已着手努力确定能够选择性杀死衰老细胞（即所谓的衰老细胞裂解剂）而不影响非衰老细胞的化合物。截至目前，已有40多种化合物表现出衰老细胞裂解特性，为临床前研究中逆转或改善与年龄相关的疾病带来了有前景的希望。本章介绍了衰老细胞裂解药物研究的最新进展，包括从基础科学、临床试验到临床研究等方面的调查。虽然其中许多研究在与年龄相关的干预领域取得了令人鼓舞的结果，但本章也讨论了潜在的挑战和陷阱。
